Nexsen and FlashDx Formed Joint Venture
The partners signed a term sheet to develop and commercialize a molecular Group B Streptococcus diagnostic test.
Updated on Sept. 25, 2026 in Biotech
Live Poll
Should medical diagnostic companies prioritize faster global market expansion for new diagnostic tests?
Nexsen Limited and FlashDx Shenzhen have signed a 50:50 joint venture to create a molecular diagnostic for Group B Streptococcus. The partnership aims to enhance existing testing capabilities for hospital and antenatal screening.
Why it matters
The venture seeks to improve detection of low bacterial levels by combining FlashDx manufacturing technology with a sample-preparation enhancement developed by Nexsen.
The joint venture utilizes a 50:50 ownership model to integrate proprietary molecular diagnostic technology. Nexsen will lead and provide funding for all upcoming regulatory activities.
The players
Nexsen Limited
Nexsen Limited is a technology firm that specializes in developing sample-preparation enhancements for medical diagnostics.
FlashDx Shenzhen
FlashDx Shenzhen is a diagnostic manufacturer that holds an existing CE-marked molecular Group B Streptococcus test.
The details
The collaboration focuses on developing tools for hospital, intrapartum, and antenatal screening. Nexsen plans to pursue both US FDA 510(k) clearance and EU In Vitro Diagnostic Medical Devices Regulation conformity to support international distribution.
Timeline
September 25, 2026: The partnership was publicly announced via a signed term sheet.
The Tech Race
The partnership marks a shift toward specialized diagnostic hardware that integrates niche enhancement layers to improve clinical sensitivity. By aligning with EU and US regulatory frameworks, the companies aim to capture significant market share in the global molecular testing sector.
Clinicians and hospital staff may eventually benefit from more accurate and reliable screening tools for Group B Streptococcus during pregnancy. Enhanced sensitivity could lead to earlier detection and improved patient monitoring in hospital settings.
The takeaway
Advancements in molecular diagnostics can lead to significant improvements in early disease screening. Healthcare providers should monitor for improved detection capabilities as these new diagnostic standards reach the market.
Further reading
Learn more about the latest innovations in Biotech.
Live Poll
Should medical diagnostic companies prioritize faster global market expansion for new diagnostic tests?
